https://www.selleckchem.com/
OBJECTIVE Several pharmacological treatments are actually recommended for Raynaud's phenomenon (RP) secondary to systemic sclerosis, but they only have modest efficacy. A way to efficiently identify new drugs is drug repurposing, which can be based on signature matching. The signature could be derived from chemical structures, pharmacological affinity profile or adverse event profile. We propose to use the WHO pharmacovigilance database to generate repositioning hypotheses for treatments of RP through adverse event signature matching. METHODS We first scree
Gefällt mir
Kommentar
Teilen
